Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Subjects up to the age of 65 years with newly diagnosed multiple myeloma requiring treatment
are eligible. Minimal pretreatment (2 cycles of chemotherapy; local irradiation; surgery) is
permitted. After enrollment, patients are to receive four cycles of RAD induction treatment:
a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone. If at least a
minimal response is achieved to RAD, they will undergo chemomobilization (cyclophosphamide,
etoposide) of peripheral blood stem cells and one uniform cycle of high-dose melphalan
chemotherapy followed by a first stem cell transplant. If any of the high-risk features (such
as elevated beta 2-microglobulin, adverse cytogenetic factors, elevated LDH, Ig A isotype)
were present at diagnosis, patients will be allocated to a consolidative allogeneic
transplant following dose-reduced conditioning. If no appropriate donor is available, the
patient does not consent or lacks of high-risk features a second autograft following
high-dose melphalan will be delivered. All patients will proceed to lenalidomide maintenance
(one year) following hematopoietic reconstitution.